{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T18:30:44Z","timestamp":1776709844323,"version":"3.51.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006229","name":"Oak Ridge Institute for Science and Education","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100006229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>While clinical trials are considered the gold standard for detecting adverse events, often these trials are not sufficiently powered to detect difficult to observe adverse events. We developed a preliminary approach to predict 135 adverse events using post-market safety data from marketed drugs. Adverse event information available from FDA product labels and scientific literature for drugs that have the same activity at one or more of the same targets, structural and target similarities, and the duration of post market experience were used as features for a classifier algorithm. The proposed method was studied using 54 drugs and a probabilistic approach of performance evaluation using bootstrapping with 10,000 iterations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of 135 adverse events, 53 had high probability of having high positive predictive value. Cross validation showed that 32% of the model-predicted safety label changes occurred within four to nine years of approval (median: six years).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This approach predicts 53 serious adverse events with high positive predictive values where well-characterized target-event relationships exist. Adverse events with well-defined target-event associations were better predicted compared to adverse events that may be idiosyncratic or related to secondary target effects that were poorly captured. Further enhancement of this model with additional features, such as target prediction and drug binding data, may increase accuracy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12859-020-3509-7","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T19:03:17Z","timestamp":1588186997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Predicting potential adverse events using safety data from marketed drugs"],"prefix":"10.1186","volume":"21","author":[{"given":"Chathuri","family":"Daluwatte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schotland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith K.","family":"Burkhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5487-5692","authenticated-orcid":false,"given":"Rebecca","family":"Racz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,29]]},"reference":[{"key":"3509_CR1","unstructured":"Woodcock J. FDA Voice [Internet]2018. Available from: https:\/\/blogs.fda.gov\/fdavoice\/index.php\/2018\/06\/fda-proposes-process-modernization-to-support-new-drug-development\/ [cited 2018]."},{"issue":"10","key":"3509_CR2","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","volume":"9","author":"PB Ferrell Jr","year":"2008","unstructured":"Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9(10):1543\u20136.","journal-title":"Pharmacogenomics."},{"key":"3509_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jbi.2015.01.011","volume":"54","author":"M Yang","year":"2015","unstructured":"Yang M, Kiang M, Shang W. Filtering big data from social media--building an early warning system for adverse drug reactions. J Biomed Inform. 2015;54:230\u201340.","journal-title":"J Biomed Inform"},{"issue":"3","key":"3509_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/cpt.320","volume":"99","author":"R Ball","year":"2016","unstructured":"Ball R, Robb M, Anderson SA, Dal PG. The FDA's sentinel initiative--a comprehensive approach to medical product surveillance. Clin Pharmacol Ther. 2016;99(3):265\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"3509_CR5","unstructured":"FDA. FAERS Public Dashboard [Available from: https:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm070093.htm]."},{"issue":"2","key":"3509_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1177\/0192623313486967","volume":"42","author":"L Zhang","year":"2014","unstructured":"Zhang L, Zhang J, Shea K, Xu L, Tobin G, Knapton A, et al. Autophagy in pancreatic acinar cells in caerulein-treated mice: immunolocalization of related proteins and their potential as markers of pancreatitis. Toxicol Pathol. 2014;42(2):435\u201357.","journal-title":"Toxicol Pathol"},{"issue":"Suppl 1","key":"3509_CR7","doi-asserted-by":"publisher","first-page":"i73","DOI":"10.1136\/amiajnl-2011-000417","volume":"18","author":"S Vilar","year":"2011","unstructured":"Vilar S, Harpaz R, Chase HS, Costanzi S, Rabadan R, Friedman C. Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. J Am Med Inform Assoc. 2011;18(Suppl 1):i73\u201380.","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"3509_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/clpt.2011.81","volume":"90","author":"Y Pouliot","year":"2011","unstructured":"Pouliot Y, Chiang AP, Butte AJ. Predicting adverse drug reactions using publicly available PubChem BioAssay data. Clin Pharmacol Ther. 2011;90(1):90\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"3509_CR9","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/pds.3493","volume":"22","author":"H Gurulingappa","year":"2013","unstructured":"Gurulingappa H, Toldo L, Rajput AM, Kors JA, Taweel A, Tayrouz Y. Automatic detection of adverse events to predict drug label changes using text and data mining techniques. Pharmacoepidemiol Drug Saf. 2013;22(11):1189\u201394.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl 4","key":"3509_CR10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1472-6947-15-S4-S1","volume":"15","author":"J Zhao","year":"2015","unstructured":"Zhao J, Henriksson A, Asker L, Bostrom H. Predictive modeling of structured electronic health records for adverse drug event detection. BMC Med Inform Decision Making. 2015;15(Suppl 4):S1.","journal-title":"BMC Med Inform Decision Making"},{"issue":"10","key":"3509_CR11","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/MLR.0b013e31825f63bf","volume":"50","author":"MJ Schuemie","year":"2012","unstructured":"Schuemie MJ, Coloma PM, Straatman H, Herings RM, Trifiro G, Matthews JN, et al. Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods. Med Care. 2012;50(10):890\u20137.","journal-title":"Med Care"},{"issue":"3","key":"3509_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/jat.3366","volume":"37","author":"J Strickland","year":"2017","unstructured":"Strickland J, Zang Q, Paris M, Lehmann DM, Allen D, Choksi N, et al. Multivariate models for prediction of human skin sensitization hazard. J Appl Toxicol. 2017;37(3):347\u201360.","journal-title":"J Appl Toxicol"},{"key":"3509_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jbi.2013.10.008","volume":"47","author":"R Xu","year":"2014","unstructured":"Xu R, Wang Q. Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA adverse event reporting system (FAERS). J Biomed Inform. 2014;47:171\u20137.","journal-title":"J Biomed Inform"},{"issue":"3","key":"3509_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.yrtph.2009.11.005","volume":"56","author":"AA Frid","year":"2010","unstructured":"Frid AA, Matthews EJ. Prediction of drug-related cardiac adverse effects in humans--B: use of QSAR programs for early detection of drug-induced cardiac toxicities. Regul Toxicol Pharmacol. 2010;56(3):276\u201389.","journal-title":"Regul Toxicol Pharmacol"},{"key":"3509_CR15","doi-asserted-by":"crossref","unstructured":"Schotland P, Racz R, Jackson D, Levin R, Strauss DG, Burkhart K. Target-adverse event profiles to augment Pharmacovigilance: a pilot study with six new molecular entities. CPT Pharmacometrics Syst Pharmacol. 2018;7(12):809\u201317.","DOI":"10.1002\/psp4.12356"},{"key":"3509_CR16","unstructured":"ATC\/DDD Index 2018: World Health Organization.\u00a0 [Available from: https:\/\/www.whocc.no\/atc_ddd_index\/]."},{"key":"3509_CR17","doi-asserted-by":"crossref","unstructured":"Roth BL, Lopez E, Patel S, Kroeze WK. The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches? Neuroscientist. 2000;6(4):252\u201362.","DOI":"10.1177\/107385840000600408"},{"issue":"D1","key":"3509_CR18","doi-asserted-by":"publisher","first-page":"D945","DOI":"10.1093\/nar\/gkw1074","volume":"45","author":"A Gaulton","year":"2017","unstructured":"Gaulton A, Hersey A, Nowotka M, Bento AP, Chambers J, Mendez D, et al. The ChEMBL database in 2017. Nucleic Acids Res. 2017;45(D1):D945\u2013D54.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"3509_CR19","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1592\/phco.24.13.1099.38090","volume":"24","author":"A Szarfman","year":"2004","unstructured":"Szarfman A, Tonning JM, Doraiswamy PM. Pharmacovigilance in the 21st century: new systematic tools for an old problem. Pharmacotherapy. 2004;24(9):1099\u2013104.","journal-title":"Pharmacotherapy."},{"issue":"2","key":"3509_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/bcpt.12655","volume":"120","author":"JT Horsfall","year":"2017","unstructured":"Horsfall JT, Sprague JE. The pharmacology and toxicology of the 'Holy Trinity'. Basic Clin Pharmacol Toxicol. 2017;120(2):115\u20139.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"3509_CR21","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.neuron.2016.04.040","volume":"90","author":"JC Lemos","year":"2016","unstructured":"Lemos JC, Friend DM, Kaplan AR, Shin JH, Rubinstein M, Kravitz AV, et al. Enhanced GABA transmission drives Bradykinesia following loss of dopamine D2 receptor signaling. Neuron. 2016;90(4):824\u201338.","journal-title":"Neuron."},{"key":"3509_CR22","unstructured":"MedDRA: Medical Dictionary for Regulatory Activities [Available from: https:\/\/www.meddra.org\/]."},{"issue":"18","key":"3509_CR23","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1001\/jama.2017.5150","volume":"317","author":"NS Downing","year":"2017","unstructured":"Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun JD, Krumholz HM, et al. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA. 2017;317(18):1854\u201363.","journal-title":"JAMA."},{"issue":"D1","key":"3509_CR24","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074\u2013D82.","journal-title":"Nucleic Acids Res"},{"key":"3509_CR25","unstructured":"Elsevier. [Available from: https:\/\/www.embase.com\/#search]."},{"key":"3509_CR26","volume-title":"Approved Drug Products with Therapeutic Equivalence Evaluations","author":"FDA","year":"2018","unstructured":"FDA. Approved Drug Products with Therapeutic Equivalence Evaluations. 38th ed; 2018.","edition":"38"},{"key":"3509_CR27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/978-3-540-78246-9_38","volume-title":"Data Analysis, Machine Learning and Applications","author":"MRCN Berthold","year":"2008","unstructured":"Berthold MRCN, Dill F, Gabriel TR, Kotter T, Meinl T, Ohl P, Sieb C, Thiel K, Wiswedel B, KNIME. The Konstanz Information Miner. In: BH PC, Schmidt-Thieme L, Decker R, editors. Data Analysis, Machine Learning and Applications. Berlin: Springer; 2008. p. 319\u201326."},{"key":"3509_CR28","unstructured":"Meyer D, Hornik K, Weingessel A, Leisch F. e1071: Misc Functions of the Department of Statistics, Probability Theory Group (Formerly E1071). R package version 1.6\u20138 ed2017. https:\/\/cran.r-project.org\/web\/packages\/e1071\/index.html."},{"issue":"3","key":"3509_CR29","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/jamia\/ocv153","volume":"23","author":"TA Kass-Hout","year":"2016","unstructured":"Kass-Hout TA, Xu Z, Mohebbi M, Nelsen H, Baker A, Levine J, et al. OpenFDA: an innovative platform providing access to a wealth of FDA's publicly available data. J Am Med Inform Assoc. 2016;23(3):596\u2013600.","journal-title":"J Am Med Inform Assoc"},{"issue":"6","key":"3509_CR30","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-020-3509-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-020-3509-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-020-3509-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T23:07:51Z","timestamp":1619651271000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-020-3509-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,29]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3509"],"URL":"https:\/\/doi.org\/10.1186\/s12859-020-3509-7","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,29]]},"assertion":[{"value":"25 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RR\u2019s spouse is an employee of AstraZeneca. All other authors have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}